Insider Trading Alert - SEAS, REGN And ALTR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Aug. 27, 2014, 98 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $66.82 to $18,231,262.91.

Highlighted Stocks Traded by Insiders:

SeaWorld Entertainment (SEAS) - FREE Research Report

Helmstedter Scott, who is Chief Creative Officer at SeaWorld Entertainment, sold 2,000 shares at $20.48 on Aug. 27, 2014. Following this transaction, the Chief Creative Officer owned 151,637 shares meaning that the stake was reduced by 1.3% with the 2,000-share transaction.

The shares most recently traded at $20.60, up $0.12, or 0.57% since the insider transaction. Historical insider transactions for SeaWorld Entertainment go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 7,678
  • 24-Week # shares sold: 30,349

The average volume for SeaWorld Entertainment has been 2.6 million shares per day over the past 30 days. SeaWorld Entertainment has a market cap of $1.8 billion and is part of the services sector and leisure industry. Shares are down 27.53% year-to-date as of the close of trading on Wednesday.

SeaWorld Entertainment, Inc. operates as a theme park and entertainment company in the United States. The stock currently has a dividend yield of 4.1%. The company has a P/E ratio of 18.8. Currently, there are 3 analysts who rate SeaWorld Entertainment a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SEAS - FREE

TheStreet Quant Ratings rates SeaWorld Entertainment as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full SeaWorld Entertainment Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Goldstein Joseph L, who is Director at Regeneron Pharmaceuticals, sold 2,000 shares at $350.31 on Aug. 27, 2014. Following this transaction, the Director owned 4,000 shares meaning that the stake was reduced by 33.33% with the 2,000-share transaction.

The shares most recently traded at $350.01, down $0.30, or 0.09% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares bought: 255
  • 4-Week # shares sold: 23,674
  • 12-Week # shares bought: 255
  • 12-Week # shares sold: 23,674
  • 24-Week # shares bought: 255
  • 24-Week # shares sold: 23,674

The average volume for Regeneron Pharmaceuticals has been 833,900 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $35.1 billion and is part of the health care sector and drugs industry. Shares are up 27.17% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 100.6. Currently, there are 8 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Altera (ALTR) - FREE Research Report

Hata William, who is Sr VP, WW Ops & Engineering at Altera, sold 119,408 shares at $34.62 on Aug. 27, 2014. Following this transaction, the Sr VP, WW Ops & Engineering owned 17,793 shares meaning that the stake was reduced by 87.03% with the 119,408-share transaction.

The shares most recently traded at $34.72, up $0.10, or 0.28% since the insider transaction. Historical insider transactions for Altera go as follows:

  • 4-Week # shares sold: 26,635
  • 12-Week # shares sold: 31,825
  • 24-Week # shares sold: 36,699

The average volume for Altera has been 2.4 million shares per day over the past 30 days. Altera has a market cap of $10.7 billion and is part of the technology sector and electronics industry. Shares are up 7.23% year-to-date as of the close of trading on Wednesday.

Altera Corporation, a semiconductor company, designs, manufactures, and sells programmable logic devices (PLD), HardCopy application-specific integrated circuit (ASIC) devices, power system-on-chip devices (PowerSoCs), pre-defined design building blocks, and proprietary development software. The stock currently has a dividend yield of 2.08%. The company has a P/E ratio of 24.1. Currently, there are 12 analysts who rate Altera a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALTR - FREE

TheStreet Quant Ratings rates Altera as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Altera Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists